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A B S T R A C T
Treatment of pulmonary hypertension has progressed by recently developed pulmonary arterial
hypertension-targeted drugs. However, long-term survival of the patients with idiopathic/heritable
pulmonary arterial hypertension is still suboptimal. To improve the outcomes, treatment goals of
pulmonary hypertension were proposed at the 5th World Symposium on Pulmonary Hypertension held
at Nice, France in 2013; parameters were obtained from cardiopulmonary exercise test, blood tests,
echocardiography, and magnetic resonance imaging. In particular, parameters evaluating right
ventricular function have been highlighted because survival of the patients with pulmonary arterial
hypertension is closely related to right ventricular function. However, treatment speciﬁcally targeted to
improve right ventricular function in pulmonary hypertension is not yet established. In this setting, we
need to maintain or improve right ventricular function with available vasodilators. In this review,
we focus on the following two points: (1) Why can pulmonary arterial hypertension-targeted drugs
improve right ventricular function without an apparent decrease in pulmonary artery pressure? (2) Are
proposed goals sufﬁcient to improve long-term prognosis of the patients? Further, we will discuss what
would be the appropriate goal in treating patients with pulmonary arterial hypertension.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Contents
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Treatment of pulmonary arterial hypertension (PAH) has
dramatically advanced by development of PAH-targeted drugs* Corresponding author at: Department of Clinical Science, National Hospital
Organization Okayama Medical Center,1711-1 Tamasu, Kita-ku, Okayama
701-1192, Japan. Tel.: +81 86 294 9911; fax: +81 86 294 9255.
E-mail address: matsubara.hiromi@gmail.com (H. Matsubara).
http://dx.doi.org/10.1016/j.jjcc.2014.06.009
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsduring the past two decades. At present, drugs targeting three
pathways that are critical for pathogenesis and progression of PAH
are available; namely, prostacyclin analogs that supply the
deﬁcient endogenous prostacyclin, endothelin receptor antago-
nists that inhibit the up-regulated endothelin pathway, and
phosphodiesterase-5 inhibitors that compensate the down-regu-
lated nitric oxide pathway. As a result, survival rates reported in
recent registries have improved [1–3] (Fig. 1). In this review, we
will focus on idiopathic/hereditary PAH (I/HPAH) especially when
discussing patient survival because prognosis varies in other formsreserved.
[(Fig._1)TD$FIG]
Fig. 1. Kaplan–Meier survival estimates in patients with idiopathic/heritable
pulmonary arterial hypertension from reported registries. Red line indicates
survival curve from NIH registry [1]. Orange line indicates survival curve from
French registry [2]. Green line indicates survival curve from REVEAL registry [3].
Blue line indicates survival curve from Okayama Medical Center [41]. Although
cumulative survival of the patients in registry studies has been improving over
time, survival rate of the patients at Okayama Medical Center is outstanding.
Cited and modiﬁed from Refs. [1–3,41].
Table 1
Prognostic predictors in patients with idiopathic/heritable pulmonary arterial
hypertension.
Parameter Values predicting poor survival Reference
Exercise capacity
NYHA functional class III or IV [1,5,6]
6MWD <165–307m [5,7–9]
Peak VO2 <10.6–11.6ml/kg [8,10]
Hemodynamics
RAP >10–20mmHg [1,5,9,11]
mean PAP – [1]
CI <2.5 l/min/m2 [1,6,9]
PVR >32Wood units [5,11]
SVO2 <65% [6]
Biomarkers
BNP >50pg/ml [5]
NT-proBNP >1400–1800ng/l [6,11]
UA >6.4mg/dl (female)
>8.9mg/dl (male)
[10,12]
Respiratory function
% predicted DLCO <80% [1,5]
Echocardiographic measurements
Right atrial area – [13]
Pericardial effusion Presence [13]
TAPSE <1.8 cm [14]
Magnetic resonance imaging measurements
SVI <25ml/m2 [15]
RVEDVI >84ml/m2 [15]
LVEDVI <40ml/m2 [15]
NYHA, New York Heart Association functional class; 6MWD, 6-min walk
distance; Peak VO2, peak oxygen consumption; RAP, right atrial pressure; PAP,
pulmonary artery pressure; CI, cardiac index; PVR, pulmonary vascular
resistance; SvO2, mixed venous oxygen saturation; BNP, B-type natriuretic
peptide; NT-proBNP, N-terminal pro–B-type natriuretic peptide; UA, uric acid;
DLCO, carbon monoxide diffusing capacity; TAPSE, tricuspid annular plane
systolic excursion; SVI, stroke volume index; RVEDVI, right ventricular end-
diastolic volume index; LVEDVI, left ventricular end-diastolic volume index.
H. Matsubara, A. Ogawa / Journal of Cardiology 64 (2014) 243–249244of PAH in relation to coexisting disorders. In the US National
Institutes of Health (NIH) registry conducted during 1981–1985
[1], the 1-, 3-, and 5-year survival rates were 68%, 48%, and 30%,
respectively. The outcome was improved in the French registry
conducted during 2002–2003 [2] where the 1- and 3-year survival
rates were 83% and 58%, respectively. It was further improved in
the REVEAL registry conducted during 2006–2009 [3], with 1-, 3-,
and 5-year survival rates of 91%, 74%, and 65%, respectively. The
treatment algorithm for PAH was updated at the 4th World
Symposium on Pulmonary Hypertension (WSPH) held in Dana
Point, CA, USA [4]. Worldwide recognition of this evidence-based
algorithm may have contributed to the improvement in patient
survival. However, PAH remains fatal considering the fact that
survival curves show an ongoing decrease over years in the
reported registries [2,3]. To improve the long-term survival of
the patients with I/HPAH, it is necessary to identify appropriate
objective treatment goals for I/HPAH.
Prognostic factors of I/HPAH
It is essential to clarify clinically relevant prognostic factors to
identify treatment goals. At the time of the 4thWSPH, the results of
the NIH registry provided the only available data [1]. It revealed
that the relevant prognostic factors were functional class and
hemodynamics. Thus, the goal in treating PAH was set to improve
and maintain the patients’ functional class at the 4th WSPH [4].
Other recent studies have provided additional prognostic factors
besides the functional class and hemodynamic parameters;
parameters were obtained from cardiopulmonary exercise test,
blood tests, echocardiography, andmagnetic resonance imaging as
listed in Table 1 [1,5–15]. Among them, parameters representing
right ventricular function have come to be emphasized as
prognostic indicators at baseline and treatment targets.
Since the leading cause of death in I/HPAH is right ventricular
failure [1], it has been recognized that the existence of right
ventricular failurewouldworsen the prognosis of the patients. This
recognition was reﬂected in a previously proposed treatment goal.
Although PAH-targeted drugs can decrease pulmonary vascular
resistance (PVR) in patients with I/HPAH to some extent (Table 2,
[16–22]), none of the drugs are reported to be able to decrease
pulmonary artery pressure (PAP) sufﬁciently. In that case, it is
convincing that the patients’ prognosis depends on betteradaptation of the right ventricle to excessively increased afterload
[23].
Treatment goal recommended in the 5th WSPH
It was timely and meaningful to discuss treatment goals at the
5th WSPH held at Nice, France in 2013. As the committee
mentioned, the focus of pulmonary hypertension specialists has
shifted from short-term functional changes to improvements in
long-term outcomes [24]. The focus of the discussion at the 5th
WSPH was to set higher the ‘‘bar’’ of treatment goals. The
recommended treatment goals included the following: modiﬁed
New York Heart Association functional class I or II, 6-min walk
distance 380–440 m, cardiopulmonary exercise test–measured
peak oxygen consumption >15 ml/min/kg, and ventilatory equiv-
alent for carbon dioxide <45 l/min/l/min, B-type natriuretic
peptide (BNP) level toward ‘‘normal,’’ echocardiography and/or
cardiac magnetic resonance imaging demonstrating normal/near-
normal right ventricular size and function, and hemodynamics
showing normalization of right ventricular function with right
atrial pressure <8 mmHg and cardiac index >2.5–3.0 l/min/m2
[24]. Since right ventricular function came to be considered among
prognostic indicators at baseline, maintaining right ventricular
function was emphasized as the treatment goal. Then, how can we
maintain or improve right ventricular function in PAH?
Established medications to treat chronic left heart failure with
decreased ejection fraction, such as angiotensin-converting
enzyme inhibitors and beta-blockers, have no evidence to
ameliorate right heart failure of I/HPAH. Moreover, Provencher
et al. [25] reported that beta-blockers were associated with
signiﬁcant worsening in exercise capacity and pulmonary hemo-
dynamics in patientswithmoderate to severe PAH. The evidence in
Table 2
Effects of pulmonary hypertension-speciﬁc drugs on idiopathic/heritable pulmonary arterial hypertension.
Drug Reference Patient
numbersa
Duration
(months)
Drug
delivery
Dose NYHA PVR (dyn s cm5) mean PAP (mmHg)
Baseline Effect p Baseline Effect p
Bosentan [16] 21 (17) 3 po 250mg/day III 896425 223 <0.001 5413 1.6 0.013
Ambrisentan [17] 64 (39) 3 po 1–10mg/day II–III 840407 226 <0.05 4913 5.2 <0.05
Sildenaﬁl [18] 69 (44) 3 po 60mg/day II–IV 987464 122 0.01 5413 2.1 0.04
Tadalaﬁl [19] 79 (46) 4 po 40mg/day I–III 901488 209 0.039 548 4.3 0.01
Riociguat [20] 254 (149) 3 po 7.5mg/day I–IV 791453 223 <0.001 4715 4 <0.001
Treprostinil [21] 233 (134) 3 sc 9.3ng/kg/minb II–IV 207880c 280c 0.0001 621 2.3 0.0003
Epoprostenol [22] 41 (41) 3 iv 9.2 0.8 ng/kg/minb III–IV 127980 272 <0.002 612 4.8 <0.001
NYHA, New York Heart Association functional class; PVR, pulmonary vascular resistance; PAP, pulmonary artery pressure; po, per os; sc, subcutaneous; iv, intravenous.
a Total patients (patients with I/HPAH).
b Average dose.
c Pulmonary vascular resistance index (dyn s cm5m2).
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overload cannot be directly extrapolated in the treatment of right
heart failure induced by pressure overload. Digitalis is the only
recommended medication as supportive therapy in the updated
evidence-based treatment algorithm in PAH [26]; although there is
no evidence for long-term effect of digitalis on right heart failure in
patientswith PAH. The sole currently availablemethod tomaintain
or improve right heart function in I/HPAH is to use vasodilators
approved for treatment of PAH [23].
Effect of vasodilators on right heart function
PVR is calculated by subtracting pulmonary capillary wedge
pressure from mean PAP and dividing it by cardiac output. It is a
useful measure of right ventricular afterload in understanding the
averaged cardiac function per minute. However, it is difﬁcult to
understand, why vasodilators decrease PVR mainly by increasing
cardiac output.
A pressure–volume diagram of the ventricle would be of help in
understanding this phenomenon. Ventricular end-systolic pres-
sure–volume relationship (ESPVR) is theoretically linear, under the
physiological condition, as shown in Fig. 2Aa [27]. The slope of
ESPVR indicates end-systolic ventricular elastance which is known
as the index of ventricular contractility [27]. The afterload of the
ventricle on the pressure–volume diagram is indicated by arterial
elastance which is derived from end-systolic pressure divided by
stroke volume [28]. In this setting, increase in stroke volume and
decrease of end-systolic pressure due to the decrease of afterload is
always proportional (Fig. 2Ab). However, the actual ESPVR is
nonlinear outside the physiological range [29,30]. ESPVR around
the extremely high end-systolic pressure shows upward convexity
as shown in Fig. 2Ba. Thus, afterload reduction obtained by
vasodilators results in increase of stroke volume with only a slight
decrease of end-systolic pressure. On the other hand, ESPVR
around the low end-systolic pressure shows a steeper slope. Thus,
equivalent after-load reduction results in a larger decrease of end-
systolic pressurewith a small increase in stroke volume. Therefore,
the actual relation between end-systolic pressure and stroke
volume indicates upward convexity as shown in Fig. 2Bb [31].
The right ventricle of the patients with PAH would be working
under this condition. Representative pressure–volume loops of the
right ventricle recorded from a patient with IPAH are shown in
Fig. 3. Although ESPVR in these loops appears linear, volume axis
intercept of extrapolated linear ESPVR is negative. Volume axis
intercept of ESPVR should be theoretically positive and hence,
ESPVR of these loopswould be nonlinear as indicated by the dotted
line. In other words, if we could reduce PVR to some extent by
vasodilators in patients with PAH who exhibit a high afterload ofthe right ventricle, increase in right heart pump function (cardiac
output) is achievable [32].
Can current therapeutic goals lead to improvement of long-
term survival?
The treatment goal recommended at the 5th WSPH [24] might
contribute to an improvement in the prognosis of PAH. However,
we consider that sufﬁcient improvement in long-term survival of
the patients cannot be obtained by the current treatment goal,
based on the following three reasons.
Firstly, the evidence for the current treatment goals would have
been obtained from the data of the patients treated by aiming at
short-term improvement of functional class. Therefore, some of
the currently recommended treatment goals appear to be
insufﬁcient to achieve long-term survival of the patients. For
example, correlation between 6-min walk distance at baseline and
patients’ survival was observed; whereas the short-term improve-
ment of 6-min walk distance was not correlated with patients’
survival in a meta-analysis of 22 randomized trials regarding PAH
[33]. The same holds true for the hemodynamic indices. Right atrial
pressure <8 mmHg and cardiac index >2.5 l/min/m2 were already
achieved in previous studies regarding epoprostenolmonotherapy.
According to the report in 2002 from France, cardiac index was
improved to 2.5 l/min/m2 in adult cases treated with epoprostenol
alone [34]. The 1-, 3-, and 5-year survival rates in the report were
85%, 63%, and 55%, respectively. In pediatric cases treated with
epoprostenol alone reported in 2004 from the USA [35], right
atrial pressure and cardiac index were improved to 6 mmHg and
4.5 l/min/m2 with 1-, 3-, and 5-year survival rates of 83%, 66%, and
57%, respectively. Although goals of hemodynamic parameters
were already achieved, the prognosis was not good enough.
Further, although these results were reported more than 10 years
ago when there were fewer treatment options, outcomes reported
in recent registry studies have not much improved [3,34,35]
(Fig. 4).
Secondly, it seems impossible to normalize the size of the
dilated right ventricle even when all other recommended goals are
achieved. Right ventricular size usually gets smaller after initiation
of treatment. However, even after hemodynamic improvement is
achieved, the size of the right ventricle cannot be normalized. As
described above, increase of cardiac output has been achieved in
many previous studies using PAH-targeted drugs. However, there
is no study reporting signiﬁcant regression of right ventricular
dilatation with current medications. A previous study has merely
demonstrated that better prognosis could be expected in patients
with normal/near-normal right ventricular size at baseline [5].
Since it has not been demonstrated that improvement of right
ventricular dilatation can be achieved by successful treatment,
[(Fig._2)TD$FIG]
Fig. 2. Schematic illustrations of pressure–volume relation of the ventricle (panel a) and ventricular pump function graph (panel b). (A) Schematic illustrationswhen assumed
that end-systolic pressure–volume relation (ESPVR) of the ventricle is always linear. (a) The slope of the line drawn from end-diastolic pressure–volume point to end-systolic
pressure–volume point in the pressure–volume loop represents arterial elastance (Ea). Ea is a measure of ventricular afterload in pressure–volume relation. When the
contractility of the ventricle is unchanged (Ees is unchanged), decrease of Ea from green dotted line to red dotted line results in increase of stroke volume (SV) and decrease of
end-systolic pressure (Pes). Additional equivalent decrease of Ea from red dotted line to blue dotted line results in the same amount of increase of SV and decrease of Peswhen
ESPVR is linear. (b) Increase in SV and decrease of Pes due to the decrease of afterload is always proportional when ESPVR is linear and thus, corresponding points to green, red
and blue loops in panel Aa indicate linear relation. (B) Schematic illustrations under actual nonlinear ESPVR of the ventricle. (a) When pressure is high, ESPVR is not linear. In
this case, decrease of Ea from green dotted line to red dotted line results in increase of SV with a slight decrease of Pes. Additional equivalent decrease of Ea from red dotted
line to blue dotted line results in smaller increase in SV and larger decrease in Pes because ESPVR is near-linear. (b) Corresponding points to green, red, and blue loops in panel
Ba indicate nonlinear relation. EDPVR, end-diastolic pressure–volume relation; EDV, end-diastolic volume; Ees, end-systolic elastance of the ventricle; Ped, end-diastolic
pressure.
H. Matsubara, A. Ogawa / Journal of Cardiology 64 (2014) 243–24946there is a leap in logic to state that normalization of the right
ventricle should be aimed at.
Thirdly, it might be difﬁcult to achieve the goals with the
currently recommended treatment algorithm. It recommends
epoprostenol only for patients with NYHA functional class IV
[26]. It is also stated that if the clinical response is inadequate,
combination therapy should be considered. These statements have
not changed from the previously proposed treatment algorithm at
the 4th WSPH [4]. However, in the current situation, the
augmentation of medical therapy, including initiation of add-on
therapy and switching to intravenous epoprostenol therapy,
appears to be performed inappropriately. For example, in the
French registry, only 10.6% of the patients were treated with
combination therapy and 15.4% of the patients were treated with
intravenous epoprostenol, although 29% of the patients had died
during 3 years follow-up [2]. In the REVEAL registry, only 47.6% of
the patients with functional class IVwere treatedwith intravenous
or subcutaneous prostacyclin [36]. This tendency can be partly
explained by the patients’ and physicians’ hesitation toward
proceeding to the most aggressive and complicated treatment
option, intravenous prostacyclin. We consider that ambiguousdeﬁnition of ‘‘adequate clinical response’’ is also a contributing
factor of delay for initiation of appropriate treatment. Many
physicians might consider the meaning of ‘‘adequate clinical
response’’ as maintaining the condition instead of improving it.
To improve the truly long-term prognosis
The essential pathophysiological feature of PAH is increased
PVR caused by remodeling of pulmonary arteries. Right heart
failure is merely the consequence of sustained overload. On the
other hand, the major cause of death in I/HPAH is right ventricular
failure; and thus, we agree with the opinion that the prevention of
right heart failure will improve the long-term prognosis of the
patients. However, it is difﬁcult to avoid right ventricular failure in
patients with PAH with high PAP. Right ventricular adaptation
progresses in response to increased wall stress due to increased
pressure [15,23]. Pulmonary arterial remodeling would also be
accelerated in response to increased vascular wall stress [37].
There are case reports that demonstrated persistence of
normalized PAP after complete abolition of the allograft in patients
who underwent single-lung transplantation for the treatment of
[(Fig._3)TD$FIG]
Fig. 3. Representative pressure–volume loops of the right ventricle recorded from a
patient with idiopathic pulmonary arterial hypertension (green loops). Preload
reduction by partial occlusion of inferior vena cava shifted the loop to leftward and
downward (indicated by arrow). Although end-systolic pressure–volume relation
(ESPVR) in these loops appears linear, volume axis intercept of extrapolated linear
ESPVR (solid line) is negative. Volume axis intercept of ESPVR should be
theoretically positive; and hence, ESPVR of these loops would be nonlinear as
indicated by dotted line.
H. Matsubara, A. Ogawa / Journal of Cardiology 64 (2014) 243–249 247IPAH [38,39]. These patients had originally been in a severe
condition with PAH requiring lung transplantation and could
survive with their single native lung for years. Their PAP was kept
at near normal level even after chronic rejection of allograft. The
fact suggests that vascular remodeling in their native lung would
have regressed. It is particularly of note that hemodynamically-
[38] or pathologically- [39] conﬁrmed regression of established
pulmonary arterial remodeling could be achieved by reducing
pressure and ﬂow with single-lung transplantation. These cases
indicate that stress of pressure and/or ﬂow would play a role in
precipitating the disease process in some patients with PAH.
Persistent high PAP and wall stress will further progress the
pulmonary artery remodeling, leading to further increase in PVR.
As a result, right ventricular remodeling will progress and lead to
maladaptation of the right ventricle. In order to stop or reverse
remodeling of the right ventricle, normalization of right ventricu-
lar wall stress should be necessary. In other words, to obtain the
long-term survival of the patients, it is necessary to achieve
sufﬁcient decrease of PAP. Needless to say, decrease in PAP
discussed here does not mean the result of deterioration of right
heart failure. It should be the result of sufﬁcient afterload reduction[(Fig._4)TD$FIG]
Fig. 4. Reported Kaplan–Meier survival estimates in patients with idiopathic/heritable pu
curve of adult patients from France [34]. Orange line indicates survival curve of pediatric
ago, there is notmuch difference between these survival curves and survival curves from
Okayama (blue line) [41] is outstanding.
Cited and modiﬁed from Refs. [3,34,35,41].of the right ventricle obtained by appropriate treatment. It needs to
be achieved by decreasing pulmonary arterial elastance without
decreasing right ventricular elastance (Fig. 2Ba). In patients with
aortic stenosis, leaving stenotic valve and optimizing medical
treatment of left heart failure expecting the left ventricular
adaptation cannot improve the long-term survival of the patients.
The same would be true for patients with I/HPAH. The primary
cause of right heart failure in I/HPAH is excessive pressure
overload. It is natural to aim at sufﬁcient reduction of afterload to
achieve the long-term survival of the patients.
Is it possible to decrease PAP in I/HPAH?
It is necessary to sufﬁciently decrease PAP, which can
ultimately stop the progression of right ventricular remodeling,
in order to achieve the long-term survival of the patients with
I/HPAH. Nevertheless the amount of reduction of PAP has not
been questioned at all in the treatment of I/HPAH in previous
WSPHs. Or rather, it has been believed that I/HPAH is a
progressive disease in nature and substantial decrease of PAP
cannot be obtained by approved PAH-targeted drugs in patients
with established I/HPAH. Indeed, according to the recent studies,
decrease of PAP has not been achieved at all. For example,
treatment effect in PVR was a 2.2% decrease and PAP did not
decrease at all in a recent registry [6].
In the early 1990s, there were no approved PAH-targeted drugs
other than epoprostenol. Physicians did not hesitate to use
epoprostenol for patients who needed it, and they aggressively
up-titrated the dosage of epoprostenol to obtain the maximal
effect. In previous reports of epoprostenol monotherapy for adult
and pediatric patients with I/HPAH, PAP decreased by 8 mmHg and
19 mmHg, with decreases of 33% and 54% in PVR [34,35]. More
than 10 years ago, sufﬁcient decrease of PVR alongwith decrease of
PAP was indeed achieved. Failure in decreasing PAP in recent
studies might be a result of the treatment aiming at short-term
improvement of functional class. We should be able to reduce PAP
with several therapeutic options if we could use them appropri-
ately, with appropriate timing.
What would be the true ‘‘goal’’ in treating patients with I/
HPAH?
The deﬁnition of goal should be reconsidered. The ‘‘goal’’ of
treatment is ideally to cure the disease. The goals stated in the
present treatment algorithm are parameters to be aimed at and
criteria to be cleared, to achieve the true ‘‘goal’’. Since the currentlylmonary arterial hypertension treatedwith epoprostenol. Red line indicates survival
patients fromUSA [35]. Although, these outcomeswere reportedmore than 10 years
REVEAL registry (green line) [3]. Compared to these data, survival rate reported from
[(Fig._5)TD$FIG]
Fig. 5. Survival rate of the patients treated at Okayama Medical Center, stratiﬁed by mean PAP at follow-up [41]. Survival rate of the patients with mean PAP  42.5 mmHg
was signiﬁcantly worse than patients with mean PAP < 42.5 mmHg (p < 0.01). (m)PAP, (mean) pulmonary artery pressure.
Cited and modiﬁed from Ref. [41].
H. Matsubara, A. Ogawa / Journal of Cardiology 64 (2014) 243–249248available data show that it is difﬁcult to cure PAH, we should at
least aim at long-term survival of the patients for more than 10
years. Then, we need to think what criteria should be fulﬁlled to
obtain better prognosis. In the recommendation at the 5th WSPH,
it is not shown how many criteria should be achieved, which
criteria should be at least fulﬁlled, and in what time period criteria
should be cleared.
We had aimed at treating patients with I/HPAH medically as a
bridge to lung transplantation. However, in 2006, we observed
PAP decreased with preserved cardiac output in some patients
with I/HPAH. At that time, we realized it is possible to reduce PAP
in patients with I/HPAH and shifted the treatment ‘‘goal’’ to aiming
at improvement of 10-year survival. To achieve our new ‘‘goal’’, we
considered it would be necessary to reduce PAP while maintaining
cardiac output. To be speciﬁc, we set the criteria of mean PAP as
<40 mmHg, based on the results of calcium channel blocker
responders whowere already reported to be able to achieve 5-year
survival of 94% [40].
In our cohort of 56 patients with I/HPAH treated from 1998 to
2012 [41], we demonstrated a better prognosis compared to any
other previous reports. PVR was reduced by 67% and PAP was
decreased by 44%with treatment. Although only about a half of the
patients could achieve mean PAP < 40 mmHg; mean survival time
from the diagnosis was 14.9  0.8 years (95% CI, 13.4–16.4 years),
with 1-, 3-, 5-, and 10-year survival rates of 98%, 96%, 96%, and 78%,
respectively. Mean PAP was an important predictor of prognosis
and all the patients who could achieve mean PAP < 42.5 mmHg
survived during the study period (Fig. 5). Among the patients who
could not achieve mean PAP < 42.5 mmHg, 5-year survival rate was
as high as 80% whereas 10-year survival rate was as low as 50%.
These results suggest that to improve long-term survival of the
patients with I/HPAH, criteria to be achieved should be a decrease of
afterload which leads to reduction of PAP (mean PAP < 42.5 mmHg).
Needless to say, this huge reduction of afterload cannot be
accomplished by treating with any single drug. Combination therapy
with different modes of action should be necessary. In fact, in
survivors of our cohort, 78% of the patients were on combination
therapy and epoprostenol was prescribed in 76% of the patients.
Our cohort included Japanese patients only and it might not
be possible to apply these results to other ethnicities. However,
since sufﬁcient reduction of PVR has already been reported to be
possible with epoprostenol in western countries in the past, it is
expected to be possible in other countries if treatment were
pursued appropriately. Although there might be difﬁculties in
obtaining consent from the patients and covering high medical
costs, we should utilize all the available treatment options for
better survival. We do not knowwhether our criteria are sufﬁcientin targeting 15- or 20-year survival. It is still to be investigated
whether there are better criteria to fulﬁll rather than to improve
pulmonary hemodynamics.
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